Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Current biomarker testing guidelines
for colorectal cancer
John Strickler, MD
Duke Cancer Center, USA
The latest in targeted therapies for advanced colorectal cancer
Richard Kim, MD
Moffitt Cancer Center, Tampa, FL
Biomarker testing and targeted therapies in colorectal cancer
Jenny Seligmann, MBChB, PhD
University of Leeds, Leeds, UK
The potential future of genomic biomarker testing and treatment in mCRC
What are the latest updates in targeted therapies in mCRC?
Benny Johnson, DO
University of Texas MD Anderson Cancer Center, Houston, TX
Targeting less common mutations
in colorectal cancer
Sebastian Stintzing, MD
Charite University Hospital, Germany
Practical considerations for genomic testing in colorectal cancer
Stacey Cohen, MD
Fred Hutchinson Cancer Center, Seattle, WA
Testing recommendations of predictive genomic biomarkers in mCRC
*NGS panels used may enable rare alterations to be picked up, i.e. NTRK
**Emerging biomarkers include HER2, MET, KRAS gene amplification, TGFα, EGFR mutations, and alterations in HER3, PI3KCA, and PTEN
±NTRK and HER2 are recommended for testing at relapse
MSI, microsatellite instability; MMR, mismatch repair; NGS, Next generation sequencing; NTRK, neurotrophic tyrosine receptor kinase fusions
Find out more on these biomarkers below:
KRAS
HER2
BRAF V600E
MSI/MMR
Coming soon…
Check out VJOncology for future updates on this topic, including…
✓ Updates from clinical trials and other targeted biomarkers in mCRC
✓ Biomarker focus: Genetic mutations in HER2, BRAF V600E, MEK, NTRK and KRAS G12C
✓ Improving access to biomarker testing in mCRC and incorporating increased testing into clinical practice
Sources
Benson AB, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021 Mar 2;19(3):329–359.
Cancer.net. Colorectal Cancer: Statistics. Available at: https://www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed: November 2022. Last Updated: May 2022.
Colorectal cancer NICE guideline [NG151]. Available at: https://www.nice.org.uk/guidance/ng151/chapter/Recommendations#molecular-biomarkers-to-guide-systemic-anti-cancer-therapy. Published January 2020. Last updated 15 December 2021.
Puccini A, et al. Biomarkers in metastatic colorectal cancer: status quo and future perspective. Cancers (Basel) 2022 Oct 3;14(19):4828.
Rachiglio AM, et al. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Explor Target Antitumor Ther 2020;1(1):53–70.
Sepulveda A, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Oncol Pract 2017;13(5):333–337.
Van Custem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386–422.
Yu I, et al. Tumor biomarker testing for metastatic colorectal cancer: a Canadian consensus practice guideline. Ther Adv Med Oncol 2022;14:17588359221111705.
This educational activity has been supported by medical education support from Seagen.
This supporter has no influence over the production of the content.
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
